Article FDA Thank You The next chapter in the ctDNA story: Still promising, not ready for prime time
Agency IQ
JULY 21, 2023
The next chapter in the ctDNA story: Still promising, not ready for prime time A recent workshop summed up the state of play for circulating tumor DNA. In addition to its use in accelerated approvals, the ORR endpoint has also been used as a surrogate endpoint for traditional approval, the FDA’s 2018 guidance on oncology endpoints notes.
40 
Let's personalize your content